Literature DB >> 26092246

Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?

Kristina L Bailey1, Andre C Kalil.   

Abstract

Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.

Entities:  

Year:  2015        PMID： 26092246     DOI： 10.1007/s11908-015-0494-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  60 in total

1.  Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

Authors:  Antonio T Freire; Vasyl Melnyk; Min Ja Kim; Oleksiy Datsenko; Oleksandr Dzyublik; Felix Glumcher; Yin-Ching Chuang; Robert T Maroko; Gary Dukart; C Angel Cooper; Joan M Korth-Bradley; Nathalie Dartois; Hassan Gandjini
Journal:  Diagn Microbiol Infect Dis       Date:  2010-10       Impact factor: 2.803

2.  In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.

Authors:  Chunguang Sun; Matthew E Falagas; Rui Wang; Drosos E Karageorgopoulos; Xuhong Yu; Youning Liu; Yun Cai; Beibei Liang; Xiujie Song; Zheyuan Liu
Journal:  J Antibiot (Tokyo)       Date:  2011-07-20       Impact factor: 2.649

3.  The impact of multidrug resistance on outcomes in ventilator-associated pneumonia.

Authors:  Rudy Tedja; Amy Nowacki; Thomas Fraser; Cynthia Fatica; Lori Griffiths; Steven Gordon; Carlos Isada; David van Duin
Journal:  Am J Infect Control       Date:  2014-03-14       Impact factor: 2.918

Review 4.  Emerging and resistant infections.

Authors:  Cornelius J Clancy; Andre C Kalil; Vance G Fowler; Elodie Ghedin; Jay K Kolls; M Hong Nguyen
Journal:  Ann Am Thorac Soc       Date:  2014-08

5.  International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009.

Authors:  Victor D Rosenthal; Hu Bijie; Dennis G Maki; Yatin Mehta; Anucha Apisarnthanarak; Eduardo A Medeiros; Hakan Leblebicioglu; Dale Fisher; Carlos Álvarez-Moreno; Ilham Abu Khader; Marisela Del Rocío González Martínez; Luis E Cuellar; Josephine Anne Navoa-Ng; Rédouane Abouqal; Humberto Guanche Garcell; Zan Mitrev; María Catalina Pirez García; Asma Hamdi; Lourdes Dueñas; Elsie Cancel; Vaidotas Gurskis; Ossama Rasslan; Altaf Ahmed; Souha S Kanj; Olber Chavarría Ugalde; Trudell Mapp; Lul Raka; Cheong Yuet Meng; Le Thi Anh Thu; Sameeh Ghazal; Achilleas Gikas; Leonardo Pazmiño Narváez; Nepomuceno Mejía; Nassya Hadjieva; May Osman Gamar Elanbya; María Eugenia Guzmán Siritt; Kushlani Jayatilleke
Journal:  Am J Infect Control       Date:  2011-09-10       Impact factor: 2.918

6.  Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia.

Authors:  P Depuydt; D Benoit; D Vogelaers; J Decruyenaere; D Vandijck; G Claeys; G Verschraegen; S Blot
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

7.  Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections.

Authors:  M Bassetti; E Repetto; E Righi; S Boni; M Diverio; M P Molinari; M Mussap; S Artioli; F Ansaldi; P Durando; G Orengo; F Bobbio Pallavicini; C Viscoli
Journal:  J Antimicrob Chemother       Date:  2008-01-03       Impact factor: 5.790

8.  Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.

Authors:  María E Pachón-Ibáñez; Fernando Docobo-Pérez; Rafael López-Rojas; Juan Domínguez-Herrera; Manuel E Jiménez-Mejias; Andrés García-Curiel; Cristina Pichardo; Luis Jiménez; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

9.  Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin.

Authors:  A Safarika; I Galani; A Pistiki; E J Giamarellos-Bourboulis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-06       Impact factor: 3.267

10.  A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.

Authors:  Marin H Kollef; Jean Chastre; Marc Clavel; Marcos I Restrepo; Bart Michiels; Koné Kaniga; Iolanda Cirillo; Holly Kimko; Rebecca Redman
Journal:  Crit Care       Date:  2012-11-13       Impact factor: 9.097
View more
  4 in total

1.  Emergence and molecular characterization of multidrug-resistant Klebsiella pneumoniae isolates harboring bla CTX-M-15 extended-spectrum β-lactamases causing ventilator-associated pneumonia in China.

Authors:  Hui Xu; Chunxiu Huo; Yao Sun; Yiheng Zhou; Yilin Xiong; Zinan Zhao; Qi Zhou; Li Sha; Beibei Zhang; Yang Chen
Journal:  Infect Drug Resist       Date:  2018-12-20       Impact factor: 4.003

2.  Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia.

Authors:  Yuqin Huang; Wenguo Wang; Qiang Huang; Zhengyan Wang; Zhuanzhuan Xu; Chaochao Tu; Dongli Wan; Miaobo He; Xiaoyi Yang; Huaqiang Xu; Hanqin Wang; Ying Zhao; Mingli Tu; Quan Zhou
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

3.  Retrospective Assessment of Ventilator-Associated Pneumonias due to Acinetobacter baumannii in an Oncology Hospital.

Authors:  Sevil Yesim Canturan; Nadim Yilmazer; Rukiye Sarikaya; Zuhal Avsar; Mustafa Ertek; Ilhan Uyaner
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-07-02

Review 4.  Ventilator-associated pneumonia in adults: a narrative review.

Authors:  Laurent Papazian; Michael Klompas; Charles-Edouard Luyt
Journal:  Intensive Care Med       Date:  2020-03-10       Impact factor: 17.440
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.